Sysmex (6869) Q1 2027 earnings summary

Executive summary

• Net sales rose to ¥130.674 billion, up 23.6% year-over-year, driven by strong growth in the Americas, Japan, and yen depreciation.

• Operating profit increased 39.5% to ¥14.8 billion, and profit attributable to owners of the parent surged 90.9% to ¥8.691 billion year-over-year.

• Growth was fueled by robust domestic and overseas expansion, with significant sales in hematology and contributions from business acquisitions.

• Higher profits resulted from increased sales, elimination of prior-year one-time inventory revaluation, and favorable foreign exchange rates.

• Cash flows from operating activities reached ¥35.595 billion, with free cash flow at ¥17.0 billion, both showing substantial year-over-year increases.

Financial highlights

• Cost of sales was ¥64.3 billion (49.3% of sales), SG&A expenses ¥42.6 billion (32.6%), and R&D expenses ¥7.2 billion (5.5%).

• Operating profit margin improved to 11.3% from 10.1% year-over-year.

• Profit attributable to owners of the parent margin rose to 6.7% from 4.3% year-over-year.

• Basic EPS increased to ¥14.17 from ¥7.30 year-over-year.

• Cash and cash equivalents increased by ¥29.517 billion to ¥113.634 billion.

Outlook and guidance

• Full-year forecast revised: net sales ¥545.0 billion (+9.0% YoY), operating profit ¥60.0 billion (+15.8%), profit attributable to owners ¥37.0 billion (+4.4%).

• Interim dividend forecast raised to ¥20.00 per share, annual to ¥40.00 per share.

• Forecasts factor in strong Americas performance, yen depreciation, and potential one-time Q2 expenses.

• Guidance may be updated pending regulatory and business developments in China.